Further upside (The Money Shot)
RaaS believes that further upside could be obtained from:
➢ The advancement of CHM 1101 to Phase II with GBM;
➢ The commencement of a Phase I frontline GBM study;
➢ The application of CHM 1101 to other indications;
➢ The advancement of CDH17 CAR T from pre-clinical stage to Phase I and beyond; and
➢ From the acquisition of additional portfolio opportunities.
Chimeric has identified melanoma, colorectal and prostate cancers as potential further targets but these are in the pre-clinical stage.
Additionally, CDH17 CAR T (CHM 2101) has set initial indications of colorectal, pancreatic, gastric and neuroendocrine cancers for its pre-clinical studies.
Chimeric has also indicated that it is seeking to expand the portfolio with additional acquisitions, which depending on their level of advancement, could add to our valuation range.
(20min delay)